PID-controller enhanced artificial β-cells

Area of Science:

• Biomedical Engineering
• Endocrinology
• Systems Biology

Background:

• Conventional diabetes management using insulin injections or pumps presents challenges in glucose level regulation.
• Artificial beta cells offer a promising alternative for diabetes treatment by sensing glucose and producing insulin.
• Existing artificial beta cell designs lack sufficient control for optimal glucose homeostasis.

Purpose of the Study:

• To address the limitations of current artificial beta cell systems.
• To propose an enhanced artificial beta cell design using Proportional-Integral-Derivative (PID) control.
• To evaluate the efficacy of PID-controlled artificial beta cells in regulating blood glucose levels.

Main Methods:

• Development of an analytical model for PID-controlled artificial beta cells.
• Numerical simulations to assess the performance of the enhanced artificial beta cell system.
• Comparison of PID-controlled artificial beta cells with conventional artificial beta cells in a simulated diabetic mouse model.

Main Results:

• The PID-controlled artificial beta cell model demonstrates improved ability to regulate glucose levels.
• PID control enables timely shutdown of insulin production, preventing hypoglycemia.
• Enhanced artificial beta cells provide greater tuning space for personalized glucose management.

Conclusions:

• PID-controlled artificial beta cells represent a significant advancement over existing designs.
• This enhanced system offers superior glucose regulation capabilities for Type 1 diabetes.
• The proposed model shows potential for more effective and personalized diabetes therapy.